Additional mRNA COVID-19 Vaccines for Moderately to Severely Immunocompromised People

“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention. ”

The fully captioned video and edited transcript will be posted within the next few days.

alert icon

This COCA Call will be held on Friday, March 27, 2020

Overview

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for additional doses of mRNA COVID-19 vaccines for moderately to severely immunocompromised people. People with immunocompromising conditions or who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Studies indicate that some immunocompromised people have a reduced immune response following a primary COVID-19 vaccine series compared to vaccine recipients who are not immunocompromised. Studies have further demonstrated that an additional mRNA COVID-19 vaccine dose after an initial 2-dose primary mRNA COVID-19 vaccine series in some immunocompromised populations may enhance immune response. 

During this COCA Call, presenters will discuss the current data on COVID-19 vaccines in immunocompromised people; the role of additional doses of mRNA COVID-19 vaccines, patients who should be considered to receive these additional COVID-19 vaccine doses, results from the August 13, 2021, Advisory Committee on Immunization Practices (ACIP) meeting, and CDC’s guidance on additional COVID-19 doses in immunocompromised people.

Presenters

Kathleen Dooling, MD, MPH
ACIP Workgroup Team Lead
Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention

Neela Goswami, MD, MPH
Clinical Guidelines Team Lead
Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA
CAPT, U.S. Public Health Service
Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention

Katherine Shealy, MPH, IBCLC
Vaccine Clinical Inquiry Management Team Lead
Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention

Facebook Live icon

Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.

Call Details

When:
Tuesday, August 17, 2021,
2:00 PM – 3:00 PM ET

Webinar Link:
https://www.zoomgov.com/j/1602130331?pwd=RStLbjVHQWdzSENWNXlVOEh2QUJLUT09external icon

Passcode: 549822

Dial In:
US: +1 669 254 5252
or +1 646 828 7666
or +1 669 216 1590
or +1 551 285 1373

International numbersexternal icon

One-tap mobile:
US: +16692545252,,1602130331#,,,,*549822#  or +16468287666,,1602130331#,,,,*549822#

Webinar ID: 160 213 0331

Add to Calendar
Sign up for COCA Newsletters and Announcements

Sign up to receive COCA Call Announcements, COCA Newsletters and other COCA resources by entering your email address:

Page last reviewed: August 14, 2021